好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Non-interventional Study of Adjunctive Lacosamide Therapy in Patients With Brain Tumor-related Epilepsy
Neuro-oncology
S30 - Brain Cancer: From Epidemiology to Quality of Life (4:25 PM-4:36 PM)
006
Data on the use of LCM for the treatment of BTRE are limited.   
To evaluate the effectiveness and tolerability of lacosamide (LCM) added to 1 or 2 antiepileptic drugs (AEDs) in the treatment of patients with brain tumor-related epilepsy (BTRE) due to low-grade primary brain tumor.

Prospective, multicenter, single-arm, non-interventional study with a 6-month observation period (EP0045; NCT02276053). LCM was added to existing treatment with 1 or 2 AEDs. Patients aged ≥16 years with BTRE secondary to low-grade glioma (WHO Grade I-II) were eligible. Primary endpoints: percentage of patients experiencing a ≥50% reduction in seizure frequency from Baseline to Month 6; Patient’s Global Impression of Change (PGIC) rating at Month 6. Secondary endpoints: Kaplan-Meier estimated retention rate and change from Baseline in quality-of-life to Month 6 (EQ-5D-5L and MDASI-BT). Safety variables: occurrence of adverse drug reactions (ADRs) and ADRs leading to discontinuation.

 

93 patients started LCM (mean [SD] age: 44.5 [14.7] years; 54% male); 14 (15%) patients withdrew from the study by 6 months. At 6-months, 71% of all patients had noted ≥50% reduction in seizures, 32% of whom were seizure free. Improvements on PGIC were reported by 53% of all patients. The estimated 6-month retention rate was 86%. Quality of life (EQ-5D-5L) and symptoms outcome measures (MDASI-BT) remained stable. ADRs leading to discontinuation occurred in 4.3% of patients, most commonly vertigo (2.2%).   

 

This is the first prospective, multicenter study focusing on epilepsy due to homogenous low grade gliomas treated with LCM. The results suggest that LCM reduces seizures in patients with resistant BTRE. The majority of patients noticed a clinical improvement with the addition of LCM. Observed ADRs were consistent with the known safety profile of LCM.

Authors/Disclosures
Roberto Ruda, MD (Ospedale San Giacomo)
PRESENTER
Dr. Ruda has nothing to disclose.
Bjorn Steiniger Brach
PRESENTER
No disclosure on file
No disclosure on file
Marc De Backer, MD, FBCPM, MBA No disclosure on file
Jane Chan, MD (Jane Chan, MD PC) No disclosure on file
No disclosure on file
Iryna Leunikava No disclosure on file
No disclosure on file
No disclosure on file